Introduction
============

Differentiating malignant adnexal masses from the benign ones is an important issue in gynecology, since the management (medical or surgical), type of surgery and prognosis of the patients depend on the benignity or malignancy of the lesions (Siegel et al., 2016). Routinely, ultrasound assessment is used for the characterization of adnexal masses. However, up to 20% of such lesions identified by ultrasound cannot be determined via this method (Imaoka et al., 2006; Bent et al., 2006). In these cases, contrast-enhanced MRI is now widely accepted as the next best step for the characterization of the mass and has been shown to offer a high specificity and sensitivity for differentiating among benign and malignant lesions (Kuhl et al., 2000; Sohaib et al., 2003; Bazot et al., 2006)

Even after using this modality, some adnexal masses still remain indeterminate (Imaoka et al., 2006), for which diffusion weighted MRI (DWI) has been suggested as the solution, but enough evidence was not available to support the fact that DWI could independently characterize an adnexal mass (Torbati et al., 2014; Thomassin-Naggara et al., 2005). Accordingly, Thomassin Naggara et al. proposed the application of dynamic contrast-enhanced MRI (DCE-MRI), in which tissue enhancement is evaluated according to the time. This method is more accurate than conventional contrast enhanced MRI and could differentiate among the benign and malignant lesions on the basis of the differences in their enhancement parameters (Thomassin Naggara et al., 2008).

Three separate qualitative, semi-quantitative and quantitative parameters can be used in DCE-MRI to gather different types of information from the imaging procedure. For the qualitative assessment, a time-intensity curve (TIC) is drawn and according to the temporal changes of the curve, conclusions are made regarding the risk of malignancy (Kuhl et al., 1999). This method is user-friendly, and TIC could be drawn by the radiologist on the MRI machine workstation and does not need any complicated mathematical assessments by a physicist. As for the semi-quantitative evaluation, the parameters are calculated by Matlab software based on the time intensity curve, including the maximum signal intensity (SImax), the maximum signal intensity relative to the tissue signal intensity on the non-enhanced T1-weighted sequence (SIrel), the wash-in rate (WIR) and the area under the curve of the first 60 seconds in the time-intensity curve (AUC-60).

In the quantitative assessment, the transfer constant (Ktrans), rate constant (Kep), blood volume (Vb), and extravascular extracellular volume fraction (Ve) were calculated using a pharmacokinetic model and microcirculation parameters on the basis of a higher neoangiogenesis and vascular permeability in malignant lesions.

Previous surveys have assessed the effectiveness of DCE-MRI in differentiating among the malignant and benign lesions of various tumors such as prostate, breast and ovaries (Kuhl et al., 2000; Ocak et al., 2007; Bernardin et al., 2012). The three different qualitative, semi-quantitative, and quantitative methods of DCE-MRI have also been compared for prostate and breast cancers, but no such studies are available for adnexal masses. Accordingly, we aimed to compare the diagnostic value of multiple qualitative, semi-quantitative, and quantitative dynamic contrast-enhanced MRI parameters in this study.

Materials and Methods
=====================

In this prospective study, the diagnostic value of different qualitative, semi-quantitative and quantitative parameters of DCE-MRI in the characterization of adnexal masses was evaluated. The study protocol was approved by the ethics committee. Informed written consent was obtained from all patients who were willing to participate in the study and all the gathered data were considered confidential.

*Patients*

All the women who were scheduled for adnexal mass surgery or given at least one year's follow- up period to confirm the benignity of their lesion had been evaluated between March, 2014 and June, 2015. Patients who met the inclusion and exclusion criteria of the survey were included as the study population.

*The inclusion criteria were as follows:*

Pathology-proven adnexal mass with surgery (laparoscopic or open surgery) or at least a one-year follow up to confirm a benign diagnosis

Underwent DCE-MRI with acceptable quality images (lacks image artifacts or other technical issues)

Presence of solid enhancing components on the tumor that are at least 3mm in diameter.

*The exclusion criteria included:*

Any reason that prohibits the patients from undergoing DCE-MRI such as claustrophobia, inability to lie still for 30-60 minutes, weighing over 120 kg, having an implant, cardiac pacemaker, insulin pump or cochlear implant, fixator of the spine, brain aneurysm clips, pregnancy, severe respiratory disorder or any contraindication for contrast injection like GFR under 30ml/min

No pathology report or an indistinctive diagnosis in the report or a follow-up period of less than one year to confirm a benign lesion.

*Not willing to participate*

*Imaging Protocol*

Magnetic resonance imaging was performed using 3-Tesla MR (Siemens, MAGNTOM Trio, Avanto, phased array coil surface) in 31 patients. After fasting for 3 hours, the patients received 20mg of Hyoscine Butylbromide intramuscularly to induce anti-peristaltic effects right before the MR imaging. Conventional MRI of the pelvic region was obtained through the routine protocol. The range of scan was set between the umbilicus and the pubic symphysis. Next, based on the findings of initial non-enhanced sequences, DCE-MRI was performed from the tumor's solid components (papillary projection, solid nodule, or thickened septa), using 3D VIBE sequences of 45 measurements with 5s/frame temporal resolution. Image acquisition was carried out before and immediately after a single dose of the 0.2 mL/kg gadolinium (Dotarem; Guerbet, Aulnay, France) injection at a rate of 3 mL/min, followed by 20cc of normal saline.

*Qualitative analysis*

For qualitative assessment, several regions of interest (ROI) with the largest possible ROI and pinpointed ROI were placed on the solid component of the adnexal masses or on their thick walls or septae (in adnexal masses without solid component) by a radiologist with six years of experience in gynecologic-oncology imaging, blinded to the proven diagnosis of the patients. The TIC was also drawn for the psoas muscle and myometrium. The highest curve type for each adnexal mass was selected for analysis.

The enhancement of kinetic curves or TICs were produced for the lesions by Syngo software on the Siemens workstation (Siemens, Germany). According to the temporal changes, the curves were categorized into three types ( Kuhl et al., 1999;Thomassin-Naggara et al., 2015): Type I was defined as a mildly persistent gradual increase without a shoulder, Type II as a moderate initial increase followed by a plateau and Type III as a relatively rapid uptake followed by reduction in enhancement towards the latter part of the study.

*Semi-quantitative analysis*

The same radiologist, analyzed the multiphase dynamic images obtained. In the semi-quantitative and quantitative assessments, two types of ROIs were drawn over the adnexal masses. One outlined the whole circumference of the solid part of the lesion in the section with maximum area of the tumor, referred to as the large ROI (lROI). For the second ROI, referred to as the small ROI (sROI), the solid component of the lesion with the highest enhancement was identified and a circular ROI with a diameter of greater than 3 mm was manually drawn.

sROIs were drawn for the psoas muscle and myometrium as two internal references as well. A single high signal point was also chosen in all the three ROIs of the tumor, psoas muscle and myometrium. The semi-quantitative analysis was performed using the Matlab software ( Ji et al., 2007) . The following parameters were calculated automatically:

SI~max~: maximum absolute enhancement

SI~rel~: maximum enhancement relative to the tissue signal intensity on non-enhanced T1-weighted sequence (SI~0~)

$\mathit{SI}_{\mathit{rel}} = \frac{\mathit{SI}_{\mathit{\max}} - \mathit{SI}_{0}}{\mathit{SI}_{0}} \times 100$

WIR: wash-in rate

$\mathit{WIR} = \frac{\mathit{SI}_{0} - \mathit{SI}_{\mathit{\max}}}{\mathit{time}\left( S \right)}$

AUC-60: the area under the curve for the first 60 seconds in the time-intensity curve

To reduce the inter-MRI variations, the ratios of these parameters calculated for the tumor relative to that of the psoas muscle and myometrium were also calculated for both lROI and sROI as well as the selected high-signal points in each patient.

*Quantitative analysis*

In the quantitative assessment, the transfer constant (K~trans~), rate constant (K~ep~), blood volume (Vb) and the extravascular extracellular volume fraction (Ve) were calculated using a pharmacokinetic model. The concentration of the contrast in the plasma was calculated through an arterial input function (AIF) model. The population-based AIF was calibrated to the AIF obtained from 10 randomly selected patients among our study population in whom the iliac artery was selected as the region of the arterial input. The pharmacokinetic parameters were calculated in accordance with the following formulae:

$K_{\mathit{ep}} = \frac{1}{\mathit{ttp}_{\mathit{tissue}} - \mathit{ttp}_{\mathit{plasma}}}$

$K_{\mathit{trans}} = V_{e} \times K_{\mathit{ep}}$

$V_{e} = \frac{C_{\mathit{gdtissue}}}{C_{\mathit{gdplasma}}}$

where C~gdplasma~ and C~gdtissue~ are the concentrations of contrast in plasma and tissue respectively, and ttp~plasma~and ttp~tissue~ are the times to reach the peak intensity in plasma and tissue, respectively.

Similar to the method applied for semi-quantitative analyses, the mentioned parameters were established for the psoas muscle and myometrium as well, and their corresponding ratios were also calculated for both lROI and sROI.

*Statistical analysis*

The SPSS software for windows, version 22, was used for statistical analysis (SPSS, Chicago, IL, USA, 2015). The differences in DCE-MRI variables between the two groups of benign and malignant lesions were evaluated via the independent samples t-test. The Receiver Operating Characteristic (ROC) Curve analysis was used to assess and compare the diagnostic values of the measured parameters based on the area under the ROC curves. The best cut-off values were chosen on the basis of the coordinate points of the ROC curves, and their sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated accordingly. A P-value of less than 0.05 was considered as statistically significant in all analyses.

Results
=======

Data gathered from the 31 patients was included in the analyses,the histopathology findings of which are presented in [Table 1](#T1){ref-type="table"}. As it can be seen, 17 patients had benign lesions and the remaining 14 subjects were diagnosed with malignancies.

*Qualitative analysis*

Based on the results of the qualitative analysis, all nine patients with Type I curves were found to have benign lesions, while all the ten subjects with Type III curves had malignant tumors. Among the 12 patients with Type II curves, eight (66.7%) had benign lesions and four (33.3%) had malignant ones (p\<0.001). To calculate the sensitivity, specificity, PPV, and NPV of the Type I curve for diagnosing benign lesions, Type II and III curves were grouped together. The results showed a sensitivity of 53%, specificity of 100%, PPV of 100%, and NPV of 63.6%. Similarly, to calculate these parameters of the Type III curve in diagnosing malignant lesions, Type I and II curves were grouped together and the results yielded a sensitivity of 71.4%, specificity of 100%, PPV of 100%, and NPV of 80.9%.

*Semi-quantitative analysis*

[Table 2](#T2){ref-type="table"} presents the results of the semi-quantitative analysis on the data. From the evaluations performed on lROI measurements, SI~rel~ (p=0.021) and WIR (p=0.046) were found to be significantly higher in patients with malignant lesions. SI~rel~(tumor)/SI~rel~(psoas) (p=0.001) and SI~rel~(tumor)/SIrel(myometrium) (p=0.031) were also found to be significantly higher in subjects with malignant tumors. The assessments on the sROIs also showed that SI~rel~(tumor)/SI~rel~(myometrium) (p=0.009) and WIR(tumor)/WIR(myometrium) (p=0.006) were significantly higher in malignant lesions.

*Quantitative analysis*

The results of the quantitative analyses are presented in [Table 3](#T3){ref-type="table"}. As illustrated, most of the evaluated variables are found to be significantly higher among the patients with malignant lesions. The only parameters where their differences had been found to be insignificant were the V~e~ of both sROI and lROI (p=0.526 and p=0.117 respectively) and the V~b~(tumor)/V~b~(psoas) (p=0.335) of the lROIs.

*Diagnostic value of the parameters*

To assess the diagnostic value of the evaluated factors in the study, the AUC of ROC curves were calculated for each parameter. As presented in [Table 4](#T4){ref-type="table"}, the highest AUCs of lROI parameters were measured for K~trans~(tumor)/K~trans~(myometrium), AUC-60(tumor)/AUC-60 (myometrium), and V~b~(tumor)/V~b~(myometrium). The highest AUCs of parameters assessed on sROI were found in K~ep~(tumor)/ K~ep~ (myometrium), K~trans~(tumor)/K~trans~(myometrium), V~b~(tumor)/V~b~(myometrium), and AUC-60(tumor)/AUC-60(myometrium). The ROC curves of these parameters with the highest AUCs are depicted in [Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}, according to which the best cut-off value, sensitivity, specificity, PPV, and NPV were calculated. As presented in [Table 5](#T5){ref-type="table"} the K~ep~(tumor)/K~ep~(myometrium) ratio measured from sROI within the outlined ROI is the best parameter for differentiating a malignant lesion with a sensitivity of 100%, specificity of 92.3%, PPV of 91.4%, and NPV of 100%.
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###### 

Histopathology Results of the Sample Population

  ---------------------------------------------------------------
  Group                        Histopathology            Number
  ---------------------------- ------------------------- --------
  Benign\                      Bilateral endometriosis   2
  (n=17)                                                 

  Endometrioid cystadenoma     1                         

  Endometrioma                 3                         

  Fibrothecoma                 2                         

  Hemorrhagic cyst             1                         

  Mature cystic teratoma       2                         

  Mucinous cystadenoma         1                         

  Peritoneal inclusion         1                         

  Serous cystadenofibroma      2                         

  Serous cystadenoma           1                         

  TB                           1                         

  Non specified                1                         

  Malignant\                   Choriocarcinoma           1
  (n=14)                                                 

  Dysgerminoma                 1                         

  Leiomyosarcoma               1                         

  Metastases                   2                         

  Mucinus cystadenocarcinoma   1                         

  Papillary Serous\            3                         
  cystadenocarcinoma                                     

  Serous cystadenocarcinoma    5                         

  Total                                                  31
  ---------------------------------------------------------------

###### 

Semi-Quantitative Analyses

  Region   Parameter                   Malignancy      P value         
  -------- --------------------------- --------------- --------------- ---------
  lROI     SI max                      274.8 (159.8)   289.2 (87.1)    0.765
           SI rel                      53.7 (55.6)     95.7 (35.2)     0.021
           WIR                         0.68 (0.6)      1.3 (1.2)       0.046
           AUC-60                      3.7 (5.0)       12.3 (6.7)      \<0.001
           SI max ratio (psoas)        1.5 (0.8)       1.9 (0.4)       0.17
           SI rel ratio (psoas)        1.3 (1.9)       4.3 (2.6)       0.001
           WIR ratio (psoas)           1.3 (1.8)       4.6 (8.8)       0.151
           AUC-60 ratio (psoas)        1.1 (1.7)       4.3 (3.8)       0.004
           SI max ratio (myometrium)   0.9 (0.5)       1.0 (0.3)       0.531
           SI rel ratio (myometrium)   0.4 (0.6)       1.0 (0.8)       0.033
           WIR ratio (myometrium)      0.4 (0.5)       0.9 (0.5)       0.051
           AUC-60 ratio (myometrium)   0.1 (0.2)       1.2 (1.0)       0.001
  sROI     SI max                      351.1 (199.2)   361.6 (105.9)   0.861
           SI rel                      77.2 (90.4)     106.2 (30.4)    0.262
           WIR                         1.0 (0.8)       3.8 (7.4)       0.141
           AUC-60                      4.5 (5.8)       12.8 (6.5)      0.001
           SI max ratio (psoas)        2.0 (1.1)       2.4 (0.6)       0.231
           SI rel ratio (psoas)        1.9 (2.7)       4.6 (2.5)       0.009
           WIR ratio (psoas)           2.1 (2.6)       8.9 (14.2)      0.098
           AUC-60 ratio (psoas)        1.3 (1.8)       4.7 (3.6)       0.004
           SI max ratio (myometrium)   1.0 (0.5)       1.2 (0.4)       0.244
           SI rel ratio (myometrium)   0.4 (0.5)       1.0 (0.5)       0.009
           WIR ratio (myometrium)      0.5 (0.7)       1.7 (1.3)       0.006

###### 

Quantitative Analyses

  Region   Parameter                    Malignancy           P value       
  -------- ---------------------------- -------------------- ------------- ---------
  lROI     K trans                      0.3 (0.3)            0.5 (0.2)     0.015
           K ep                         0.4 (0.2)            0.6 (0.2)     0.036
           Vb                           0.2 (0.2)            0.6 (0.4)     \<0.001
           Ve                           0\. 7 (0.4)          0.9 (0.2)     0.117
           K trans ratio (psoas)        0\. 9 (1.0)          3.3 (2.9)     0.003
           K ep ratio (psoas)           0\. 8 (0.6)          1.3 (0.7)     0.028
           Vb ratio (psoas)             3255.4 (12341.3)     12.5 (24.5)   0.335
           Ve ratio (psoas)             1.0 (0.9)            2.5 (1.8)     0.004
           K trans ratio (myometrium)   0.4 (0.4)            1.4 (1.1)     0.003
           K ep ratio (myometrium)      0.5 (0.4)            1.0 (0.3)     0.006
           Vb ratio (myometrium)        0.2 (0.3)            1.3 (1.0)     0.002
           Ve ratio (myometrium)        0.7 (0.5)            1.7 (1.8)     0.05
           K trans                      0.3 (0.3)            0.5 (0.2)     0.015
           K ep                         0.4 (0.2)            0.6 (0.2)     0.036
           Vb                           0.2 (0.2)            0.6 (0.4)     \<0.001
  sROI     K trans                      0.3 (0.3)            0.5 (0.2)     0.034
           K ep                         0.4 (0.3)            0.6 (0.2)     0.018
           Vb                           0.2 (0.3)            0.6 (0.3)     0.002
           Ve                           0.8 (0.4)            0.8 (0.3)     0.526
           K trans ratio (psoas)        1.1 (1.3)            3.6 (3.2)     0.014
           K ep ratio (psoas)           0.8 (0.7)            1.5 (0.7)     0.024
           Vb ratio (psoas)             4238\. 3 (14458.2)   12.5 (20.0)   0.246
           Ve ratio (psoas)             1.3 (1.3)            2.1 (1.2)     0.059
           K trans ratio (myometrium)   0.4 (0.4)            1.4 (0.5)     \<0.001
           K ep ratio (myometrium)      0.5 (0.4)            1.1 (0.3)     \<0.001
           Vb ratio (myometrium)        0.2 (0.3)            1.4 (1.2)     0.001
           Ve ratio (myometrium)        0.7 (0.4)            1.2 (0.5)     0.018

###### 

Area Under the Curve (AUC) for Semi-Quantitative and Quantitative Parameters

  -----------------------------------------------------------------------------------
  Analysis       Region   Test Result Variable(s)      Area    Std. Error   P value
  -------------- -------- ---------------------------- ------- ------------ ---------
                          Smax                         0.528   0.124        0.817

  Semi-\         lROI     SI rel                       0.745   0.108        0.043
  quantitative                                                              

                          WIR                          0.731   0.104        0.056

                          SI max ratio (psoas)         0.71    0.115        0.082

                          SI rel ratio (psoas)         0.871   0.074        0.002

                          WIR ratio (psoas)            0.724   0.107        0.064

                          SI max ratio (myometrium)    0.626   0.116        0.297

                          SI rel ratio (myometrium)    0.829   0.084        0.006

                          WIR ratio (myometrium)       0.843   0.085        0.005

                          Smax                         0.598   0.12         0.417

                 sROI     SI rel                       0.738   0.103        0.049

                          WIR                          0.745   0.114        0.043

                          SI max ratio (myometrium)    0.682   0.113        0.132

                          SI rel ratio (myometrium)    0.794   0.096        0.015

                          WIR ratio (myometrium)       0.864   0.077        0.003

                          Ktrans                       0.86    0.076        0.003

  Quantitative   lROI     Kep                          0.776   0.096        0.022

                          Vb                           0.892   0.064        0.001

                          AUC60                        0.86    0.081        0.003

                          Ve                           0.685   0.11         0.125

                          K trans ratio (psoas)        0.881   0.068        0.002

                          K ep ratio (psoas)           0.79    0.092        0.016

                          Vb ratio (psoas)             0.738   0.108        0.049

                          AUC-60 ratio (psoas)         0.825   0.086        0.007

                          Ve ratio (psoas)             0.839   0.08         0.005

                          K trans ratio (myometrium)   0.979   0.025        \<0.001

                          K ep ratio (myometrium)      0.888   0.066        0.001

                          Vb ratio (myometrium)        0.916   0.063        0.001

                          AUC-60 ratio (myometrium)    0.951   0.041        \<0.001

                          Ve ratio (myometrium)        0.727   0.103        0.06

                 sROI     Ktrans                       0.846   0.08         0.004

                          Kep                          0.829   0.083        0.006

                          Vb                           0.888   0.066        0.001

                          AUC60                        0.888   0.074        0.001

                          Ve                           0.605   0.117        0.385

                          K trans ratio (myometrium)   0.986   0.018        \<0.001

                          K ep ratio (myometrium)      0.993   0.011        \<0.001

                          Vb ratio (myometrium)        0.972   0.028        \<0.001

                          AUC-60 ratio (myometrium)    0.937   0.047        \<0.001

                          Ve ratio (myometrium)        0.755   0.098        0.034
  -----------------------------------------------------------------------------------

###### 

Cut-off Value, Sensitivity, Specificity, PPV and NPV of the Best Diagnostic Parameters

  Region   Test Result Variable(s)      Area    Cut-off   Sensitivity   Specificity   PPV    NPV
  -------- ---------------------------- ------- --------- ------------- ------------- ------ ------
  lROI     K trans ratio (myometrium)   0.979   0.53      100           92.3          91.4   100
           AUC-60 ratio (myometrium)    0.951   0.46      90.9          92.3          90.6   92.5
           Vb ratio (myometrium)        0.916   0.4       90.9          92.3          90.6   92.5
  sROI     K ep ratio (myometrium)      0.993   0.73      100           92.3          91.4   100
           K trans ratio (myometrium)   0.986   0.82      90.9          100           100    93
           Vb ratio (myometrium)        0.972   0.49      90.9          92.3          90.6   92.5
           AUC-60 ratio (myometrium)    0.937   0.44      81.8          92.3          89.7   86.1

Discussion
==========

Differentiating among malignant adnexal masses and benign lesions is of utmost importance to determine the best course of action for the patient. Despite the vast improvements in imaging techniques and modalities, a few cases still remain indeterminate (Hricak et al., 2000). Therefore, better diagnostic tools and criteria are needed to enhance our ability to differentiate an invasive lesion from a benign one. In this regard, the superiority of DCE sequences compared with simple CE sequences for qualitative evaluation of enhancement has been established (Sohaib et al., 2003; Husband et al., 2006;Thomassin-Naggara et al., 2008; 2011). Moreover, three different analyses have been proposed to acquire further information from the DCE-MRI that might be valuable in distinguishing malignant lesions from the benign ones. Qualitative analysis categorizes the patients into three groups based on the temporal changes of enhancement, observed in the kinetic curves. The method was described by Kuhl et al., (1999), and its effectiveness was evaluated in distinction of malignant and benign breast masses. They reported a sensitivity of 91%, specificity of 83%, and a diagnostic accuracy of 86% for the Type III curves in diagnosing malignant lesion and concluded that the type III time-course is a strong predictor of malignancy. Qualitative analysis is a user-friendly and simple method compared with other mentioned methods for DCE-MRI assessment. According to the results of the present survey, an adnexal mass is benign if it presents a Type I TIC, and the mass is malignant if it presents Type III TIC, and therefore, there is no need for application of semi-quantitative and quantitative methods in these conditions.

Semi-quantitative analysis derives multiple parameters from the TICs drawn for the lesion. Bernardin et al., (2011) assessed the diagnostic value of this method in predicting malignancy in adnexal masses; they found significant differences in SImax, SIrel, and WIR between malignant and benign lesions. A cut-off WIR of equal or greater than 9.5 was found to have a specificity of 88% and PPV of 86%. In our previous study in 2014, in order to reduce inter-MRI variation we included ratios of these parameters in the lesion to that of psoas and myometrium and reached promising results (Torbati et al., 2014). WIR, AUC-60, SI~max~(tumor)/SI~max~(psoas), SI~max~(tumor)/SI~max~(myometrium), WIR(tumor)/WIR(psoas) and WIR(tumor)/WIR(myometrium) were significantly higher in malignant tumors.

Quantitative analysis is based on the higher neoangiogenesis and vascular permeability in malignant lesions ; it uses a pharmacokinetic model and microcirculation parameters. Priest et al., (2010) aimed to compare these variables between malignant and benign ovarian masses and found no significant difference between the two groups by considering K~trans~, K~ep~, V~b~, V~e~, and the AUC of the first 60 seconds in the TIC. However, Amaranth and colleagues (2013) conducted an ROC curve analysis and showed that a mean K~trans~ value of 0.56 reliably differentiates malignant lesions from benign masses with a sensitivity of 91.1%, a specificity of 90.3%, and an overall accuracy of 89.3%.

In this regard we aimed to compare the efficacy of these three analyses while adding some ratio parameters to the model in order to reduce inter-MRI variation (Torbati et al., 2014). Other than performing these analyses on the outlined ROIs of the tumor, psoas muscle and myometrium, we also measured these factors for a small ROI within the outlined ROIs and included their ratios as well. Overall, quantitative parameters were more accurate in predicting the malignancy of a lesion compared with semi-quantitative and qualitative variables. This might be attributed to the fact that these parameters are more closely related to the pathophysiologic changes in a malignant tumor. The pharmacokinetic model used for the quantitative analysis in this study was first described by Tofts in 1999 as the standard two-compartmental model that includes plasma and the extravascular extracellular space (Tofts et al., 1999). The transport of gadolinium from vasculature to tissue interstitium corresponds to the blood flow and the permeability properties of the tissue that are reflected in the K~trans~ coefficient. K~ep~ represents the reverse transport of gadolinium into the vasculature. Neoangiogenesis is the physiological basis for this model, in which many small leaky vessels develop around the tumor to provide blood and nutrients for the increased demand of the fast-growing tissue. The characteristics of micro-vessels differ among benign and malignant lesions and so do the behavior of gadolinium which is measured by the pharmacokinetic factors.

The calculated AUC of ROC curves drawn for parameters measured for lROIs were the highest in the ratios of K~trans~ (tumor)/K~trans~ (myometrium), AUC-60 (tumor)/AUC-60 (myometrium) and Vb (tumor)/Vb(myometrium). The highest AUCs of parameters assessed on high signal points were found in the ratios of K~ep~(tumor)/ K~ep~ (myometrium), K~trans~ (tumor)/K~trans~(myometrium), V~b~(tumor)/V~b~ (myometrium) and AUC-60(tumor)/AUC-60(myometrium).

Among these, the K~ep~ (tumor)/K~ep~ (myometrium) ratio measured from an sROI was found to be the best parameter for differentiating a malignant lesion from a benign mass with a sensitivity of 100%, specificity of 92.3%, PPV of 91.4%, and NPV of 100%. In comparison with the figures calculated for the qualitative method of the kinetic curves (sensitivity=71.4%, specificity=100%, PPV=100% and NPV=80.9%), this parameter seems to be considerably more accurate and reliable for diagnosing malignant lesions. The other mentioned ratios with AUCs of greater than 0.9 can also be used as diagnostic measures as well.

Based on the results of the present survey, it seems that outlining a large ROI throughout the whole solid part of the tumor (lROI) and using the mean measurements of the total area are not needed and that they do not add any value to our analyses. In contrast, it seems that using a small ROI (sROI) within the lesion would result in a higher accuracy for differentiating malignant lesions from the benign ones.

Aiming to find simpler diagnostic tools for ovarian cancer, the UK collaborative Trial of Ovarian Cancer Screening (UKCTOCS) compared the diagnostic characteristics of annual CA-125 screening plus trans-vaginal ultrasound assessment (multimodal screening) with annual screening by trans-vaginal ultrasound alone (Menon et al., 2009). The results of their robust study on 202,638 women aged 50 to 74 recruited from 13 centers in National Health Service Trusts in England, Wales, and Northern Ireland revealed a higher diagnostic value for multimodal screening method. According to their findings, for all primary ovarian and tubal cancers the multimodal screening method had a sensitivity of 89.4%, a specificity of 99.8%, and a PPV of 43.3% while these figures for trans-vaginal ultrasound alone were 84.9%, 98.2%, and 5.3%, respectively. For primary invasive epithelial ovarian and tubal cancers, the mentioned values for multimodal screening were 89.5%, 99.8%, and 35.1%, and for the ultrasound alone were 75.0%, 98.2%, and 2.8%, respectively. As can be seen there are multiple semi-quantitative and quantitative parameters in the DCE-MRI analysis that provide superior diagnostic values to the evaluated screening methods by UKCTOCS; however, the methods we evaluated should be conducted on a large sample population to yield more accurate estimates of their diagnostic characteristics. Moreover, the costs and availability of a diagnostic test is also an important factor that should be considered in choosing the best method and in this regard, multimodal screening and trans-vaginal ultrasound assessment seem to be better options. Nevertheless, to acquire concrete and reliable information on this matter, a comparison on the cost-effectiveness of these diagnostic tools is recommended.

Not including the morphological characteristics of the tumors, was one of the limitations of this study. Accordingly, we could not compare the classical morphological criteria of malignancy with the assessed parameters. Another major shortcoming of the present survey was categorizing the patients into two groups of benign or malignant lesions and not separately analyzing borderline tumors. Therefore, in order to make a decision regarding the application of these parameters as a part of evaluations for ovarian masses, further investigations are required including larger sample populations.

In conclusion, our study showed that further evaluation is not needed if the lesion has TIC Type I or Type III in qualitative DCE-MRI. Complementary quantitative analysis is only recommended for the adnexal masses with Type II TICs. Semi-quantitative and quantitative DCE-MRI parameters measured from either an lROI or sROI can be used for differentiating malignant ovarian lesions from benign masses. However, the accuracy of quantitative parameters was found to be higher than that of semi-quantitative variables, particularly when measured from sROI rather than lROI. The K~ep~ (tumor)/K~ep~ (myometrium) ratio measured from one sROI within the outlined ROI was found to be the most accurate discriminator (sensitivity=100%, specificity=92.3%, PPV=91.4% and NPV=100%).
